Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Case for TAAR1 as a Modulator of Central Nervous System Function
Grazia Rutigliano, Alice Accorroni, Riccardo Zucchi
Frontiers in Pharmacology (2018) Vol. 8
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 320
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Kenneth S. Koblan, Justine Kent, Seth C. Hopkins, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 16, pp. 1497-1506
Open Access | Times Cited: 246
A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths
P. Ken Gillman
Journal of Neural Transmission (2018) Vol. 125, Iss. 11, pp. 1707-1717
Closed Access | Times Cited: 242
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2Receptor Mechanism of Action
Nina Dedic, Philip Jones, Seth C. Hopkins, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 1, pp. 1-14
Open Access | Times Cited: 151
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Michael J. Lucido, Mandakh Bekhbat, David R. Goldsmith, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 1084-1117
Open Access | Times Cited: 70
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Zdeněk Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 120, pp. 110626-110626
Closed Access | Times Cited: 59
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
Molecular basis of human trace amine-associated receptor 1 activation
Gregory Zilberg, Alexandra Kalia Parpounas, Audrey L. Warren, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Thyroid Hormone Analogues: An Update
Riccardo Zucchi
Thyroid (2020) Vol. 30, Iss. 8, pp. 1099-1105
Open Access | Times Cited: 66
Tyramine action on motoneuron excitability and adaptable tyramine/octopamine ratios adjust Drosophila locomotion to nutritional state
Natalie Schützler, Chantal Girwert, Isabell Hügli, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 9, pp. 3805-3810
Open Access | Times Cited: 61
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr, et al.
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 89-108
Open Access | Times Cited: 54
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
Michele L. R. Heffernan, Lee W. Herman, Scott P. Brown, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 13, Iss. 1, pp. 92-98
Open Access | Times Cited: 54
Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?
Seetal Dodd, André F. Carvalho, Basant K. Puri, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 120, pp. 537-541
Closed Access | Times Cited: 51
Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review
Javier Quintero, José Ramón Gutiérrez-Casares, Cecilio Álamo
Neurology and Therapy (2022) Vol. 11, Iss. 4, pp. 1489-1517
Open Access | Times Cited: 33
Ultrasensitive quantification of trace amines based on N-phosphorylation labeling chip 2D LC-QQQ/MS
Xiqing Bian, Yida Zhang, Na Li, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 3, pp. 315-322
Open Access | Times Cited: 19
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1739-1739
Open Access | Times Cited: 6
From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency
Marco Bortolato, Gabriele Floris, Jean C. Shih
Journal of Neural Transmission (2018) Vol. 125, Iss. 11, pp. 1589-1599
Open Access | Times Cited: 56
p ‐Synephrine, ephedrine, p ‐octopamine and m ‐synephrine: Comparative mechanistic, physiological and pharmacological properties
S.J. Stohs, Mohd Shara, Sidhartha D. Ray
Phytotherapy Research (2020) Vol. 34, Iss. 8, pp. 1838-1846
Open Access | Times Cited: 48
TAAR Agonists
Zhengrong Xu, Qian Li
Cellular and Molecular Neurobiology (2019) Vol. 40, Iss. 2, pp. 257-272
Closed Access | Times Cited: 44
The relation between thyroid dysregulation and impaired cognition/behaviour: An integrative review
Manizhe Eslami‐Amirabadi, S. Ahmad Sajjadi
Journal of Neuroendocrinology (2021) Vol. 33, Iss. 3
Open Access | Times Cited: 37
Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
Seth C. Hopkins, Nina Dedic, Kenneth S. Koblan
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 33
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S. Gillissie, Taeho Greg Rhee, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 401-415
Closed Access | Times Cited: 16
Electroacupuncture alleviated depression‐like behaviors in ventromedial prefrontal cortex of chronic unpredictable mild stress‐induced rats: Increasing synaptic transmission and phosphorylating dopamine transporter
Xiaowen Cai, Mei Wu, Zhinan Zhang, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 29, Iss. 9, pp. 2608-2620
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top